Eight stock picks to play one of the healthiest corners of the market

The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.

Market Watch • Dec 11, 2025

GeneDX CEO Sells 2,158 Shares After 84% One-Year Bump

GeneDX provides an artificial intelligence-powered genetic testing platform. CEO Katherine Stueland sold about $300,000 worth of shares on Oct. 29.

The Motley Fool • Dec 9, 2025

HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

PRNewsWire • Nov 30, 2025

6 Healthcare Stocks With Strong Upward Momentum

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Benzinga • Nov 18, 2025

BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

The Motley Fool • Nov 14, 2025

Artificial Intelligence (AI) Stock Scores Vote of Confidence From Asset Manager, According to Recent Filing

Added 120,000 shares of GeneDx Holdings, an increase valued at ~$12.93 million Post-trade stake: 120,000 shares worth $12.93 million as of September 30, 2025 GeneDx Holdings is not among Telemark Asset Management's top five positions by size

The Motley Fool • Nov 11, 2025

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

Business Wire • Nov 6, 2025

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Stifel 2025 Healthcare Conference New York, New York Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET Jefferies Global Healthcare Conference London, UK Presentation: Wednesday, November 19 at 11:00 a.m. GMT Piper Sandler 37th Annual Healthcare Conference New York, New Yo.

Business Wire • Nov 4, 2025

GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Oct 28, 2025

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.

Business Wire • Oct 28, 2025